Hepatology

Saroglitazar received FDA Priority Review for adults with PBC after phase 3 data showed improved biochemical response versus placebo.

The Liver Disease Panel represents the first comprehensive library of certified healthcare algorithms to support chronic liver disease management.

Until this decision, clinicians relied on off-label, interferon-based regimens with limited efficacy.

Lee discusess DDW 2026 data linking binge drinking frequency to advanced hepatic fibrosis in SLD.

Noureddin discusses HU6’s mitochondrial uncoupling mechanism and why muscle preservation may become increasingly important in MASH care.

Catch up on updates in viral hepatitis treatment, advances in rare liver disease care, and more.

COBRA findings suggest 1 day of antibiotic treatment is preferred in acute cholangitis after adequate biliary drainage compared to longer guidelines.

Volixibat reduced cholestatic pruritus in phase 2b primary sclerosing cholangitis data, with diarrhea and liver test elevations reported.

New paired biopsy data show histologic regression after metabolic bariatric surgery in compensated MASH patients, challenging the irreversibility of cirrhosis.

Njei explains the evolving treatment landscape for MASLD and how it impacts the cost-effectiveness of noninvasive tests for screening.

Stay updated with the latest healthcare breakthroughs, including notable FDA approvals and filings, in this week’s essential news roundup.

Brelovitug achieved the FDA-specified primary endpoint for HDV RNA reduction and normalization of ALT in a phase 2b trial.

Brelovitug met the primary endpoint for virologic response and ALT normalization in the phase 2b portion of the AZURE-1 trial.

The FDA has accepted bepirovirsen's NDA for Priority Review and granted Breakthrough Therapy designation, with a PDUFA date of October 26, 2026.

Experts call for greater awareness, improved collaboration with OB/GYNs, and more proactive MASLD screening strategies for women.

Experts discuss how metabolic and hormonal factors in women influence MASLD risk, progression, and potential long-term outcomes.

Hosts are joined by Meena Bansal, MD, to discuss long-standing research gaps and what clinicians need to understand about sex-specific drivers of liver disease today.

Experts discuss diagnostic challenges, variable presentations, and strategies to improve outcomes in Wilson disease.

Clinicians discuss diagnostic gaps, treatment strategies, and multidisciplinary care in Wilson disease.

Martinez describes how IBAT inhibitors are reshaping cholestatic pruritus care, with impacts on symptoms, growth, and long-term liver outcomes.

Experts discuss interpreting genetic testing in liver disease, the role of biopsy, and how to integrate variants into clinical decision-making.

In this segment of Liver Lineup, experts discuss genetic testing in cholestatic disease, highlighting real-world cases demonstrating the value of these tests.

Q1 2026 hepatology highlights include advances in MASH, hepatitis B, gene editing for AATD, and the first approved therapy for pruritus in PBC.

Experts discuss when to use genetic testing in cholestatic disease, how to interpret results, and its growing role in diagnosis and management.

Key hepatology updates from March 2026, including a first-in-class PBC therapy, viral hepatitis insights, and emerging research in MASLD and HCC.